Overview

* Evolus Q2 2025 global net revenue rises 4% to $69.4 mln

* Company expects meaningful profitability in Q4 2025

* Launch of Evolysse drives revenue growth amid U.S. market challenges

Outlook

* Evolus ( EOLS ) expects 2025 revenue between $295 mln and $305 mln

* Company anticipates Q4 2025 profitability and annual profitability in 2026

* Evolus ( EOLS ) plans to launch Evolysse™ Sculpt in 2026 and Lips in 2027

* Company targets $700 mln revenue and 20% margin by 2028

Result Drivers

* EVOLYSSE LAUNCH - Evolysse generated $9.7 mln in Q2 2025, marking a strong debut in the filler market

* INTERNATIONAL GROWTH - Strong international sales contributed significantly to revenue increase

* U.S. MARKET CHALLENGES - U.S. toxin demand softened due to decreased consumer sentiment, impacting sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $68.70

Product mln

Revenue

Q2 Net -$17.14

Income mln

Q2 Gross 65.3%

Margin

Q2 66.5%

Adjusted

Gross

Margin

Q2 Gross $45.32

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Evolus Inc ( EOLS ) is $23.50, about 61.2% above its August 4 closing price of $9.11

* The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 56 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)